Business
Former President Donald Trump's Hush Money Trial Continues In New York
Vivek Ramaswamy (Photo by David Dee Delgado/Getty Images)

3 theories on why Vivek Ramaswamy is buying up BuzzFeed

Maybe the media company is his answer to Truth Social?

If you asked me, like, eight months ago, what would be the funniest activist investment into a struggling public company, I think “Republican presidential candidate Vivek Ramaswamy making a strategic investment in BuzzFeed” would have been a top five answer.

This morning, we got to see that fantasy come to life, as former Republican presidential candidate Vivek Ramaswamy announced that he had taken an activist stake in BuzzFeed, acquiring 2.7 million shares between $1.47 and $2.51 per share, and call options representing an additional 210,000 shares with a $2 strike price.

The filing’s Purpose of Transaction states that, “The Reporting Person (Vivek) will seek to engage in a dialogue with the Issuer's Board of Directors (the "Board") and/or management about numerous operational and strategic opportunities to maximize shareholder value, including a shift in the Company's strategy.”

My question is, what strategic opportunity is Vivek considering at this point?

An timeline of the events that led us here:

June 2021: BuzzFeed announced that it was going public through a $1.5 billion reverse merger with a SPAC in June 2021, and it was acquiring Complex Networks for $300 million ($200 million in cash, and $100 million in BuzzFeed equity).

December 2021: Days before BuzzFeed went public, 94% of the SPAC’s sponsors redeemed their shares. In SPAC deals, investors can redeem their shares for $10 cash before the deal closes, leaving BuzzFeed with just $16 million in cash in the SPAC’s trust, as well as a $150 million convertible note that it raised to help fund the Complex acquisition.

April 2023: BuzzFeed shut down its BuzzFeed News arm, and the company laid off 180 employees.

June 2023: BuzzFeed received a delisting notice from Nasdaq, as its stock price was floundering below $1.

February 2024: BuzzFeed sold Complex for $108.6 million, or roughly one third of its purchase price, and used about $66 million of the cash to pay off a revolving credit facility and redeem a portion of its convertible notes due in 2026.

And, according to their Q1 earnings report released 9 days ago, BuzzFeed lost $27 million on $45 million in revenue. The outlook isn’t good!

Of course, these are rookie loss numbers for recently IPO’d media companies. Trump Media & Technology Group, the parent company of Donald Trump’s Truth Social platform, disclosed a net loss of over $327 million in Q1, on total revenue of $770,500.

I have three hypotheses:

  1. Vivek has a plausible vision to return BuzzFeed to its former glory.

  2. Vivek thinks he has a plausible vision to return BuzzFeed to its former glory, but the company is probably cooked.

  3. After a poor finish in the Republican primaries, Vivek decided to emulate Trump to prepare for a 2028 run, and, as part of the decision, he found it necessary to, like Trump, own a large stake in a publicly traded media company.

Whatever the reason, Vivek’s purchase inspired investor confidence, with BuzzFeed finishing the day up 20%.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.